Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Gastrointestinal tumours, colorectal

5222 - InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial.


22 Oct 2018


Proffered paper session - Gastrointestinal tumours, colorectal


Cytotoxic Therapy

Tumour Site

Anal Cancer


Sheela Rao


S. Rao1, F. Sclafani2, C. Eng3, M. Grønlie Guren4, R.A. Adams5, A. Benson6, D. Sebag-Montefiore7, E. Segelov8, A. Bryant9, C. Peckitt10, A. Roy11, M.T. Seymour12, J. Welch13, M.P. Saunders14, R. Muirhead15, J. Bridgewater16, S. Falk17, R. Glynne-Jones18, D. Arnold19, D. Cunningham20

Author affiliations

  • 1 Gi Unit, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 2 Medicine-gi & Lymphoma Unit, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB
  • 3 Department Of Gastrointestinal Medical Oncology,, M. D. Anderson Cancer Center, Houston/US
  • 4 Gi Unit, Oslo University Hospital, 424 - Oslo/NO
  • 5 1division Of Cancer And Genetics, Cardiff University, CF14 4XN - Cardiff/GB
  • 6 Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago/US
  • 7 Gi Unit, University of Leeds, LS2 9LU - Leeds/GB
  • 8 Oncology, Monash Medical Centre, 3168 - Clayton/AU
  • 9 Gi Unit, Royal Marsden Hospital NHS Foundation Trust, SM25PT - London/GB
  • 10 R&d, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 11 Gi Unit, Flinders Centre for Innovation in Cancer, 5042 - Bedford Park/AU
  • 12 Medical Oncology, St. James's University Hospital Leeds, LS9 7TF - Leeds/GB
  • 13 Center For Global Health, NCI-CGH, New York/US
  • 14 Gi Unit, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 15 Oncology, Churchill Hospital, Oxford/GB
  • 16 Oncology, University College London Hospitals, London/GB
  • 17 Bristol Haematology And Cancer Centre, Bristol University Hospitals NHS Foundation Trust, Bristol/GB
  • 18 Radiotherapy, Mount Vernon Cancer Centre, HA6 2RN - Northwood/GB
  • 19 2. Med. Abteilung, Asklepios Klinik Altona, 22763 - Hamburg/DE
  • 20 Medicine, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5222


Whilst advanced squamous cell carcinoma of the anal canal (SCCA) is a rare disease incidence has risen by 2%/year for the past decade. There is no consensus on management of these pts who generally have a poor overall survival (OS) and to date no randomised trial has been completed. The combination of fluoropyrimidine /platinum agents is often considered standard 1st line therapy whilst taxanes have shown activity. We conducted a randomised phase II study to establish a standard of care.


Eligible pts randomised in 1:1 ratio to CDDP (60 mg/m2, D1q21)/5-FU (1000 mg/m2/24h, D1-4q21) or C (AUC 5, D1q28)/P (80 mg/m2, D1,8,15q28). Stratification factors were performance status (PS), extent of disease, HIV status & country. Primary endpoint was response rate (RR). Based on a RR estimate of 40% in the CDDP/5-FU arm, 80 pts were required to detect 10% difference in RR between the 2 arms with 80% power (phase II selection trial pick the winner design). Secondary endpoints include progression-free survival (PFS), OS, toxicity, quality of life & feasibility.


Between 2014-2017, 91 pts were randomised (46 CDDP/5-FU, 45 CP) from 31/60 centres ;Median age 61 yrs ;Female 67%;12% locally advanced, 88% metastatic. RR :57.1% in CDDP/5-FU and 59.0 % in CP. Median PFS: 5.7 mths for CDDP/FU versus 8.1mths for CP, p=0.375. Median OS 12.3 mths for CDDP/FU versus 20 mths for CP, HR 2.0 p =0.014. Grade ≥3 toxicity occurred in 32 pts (76%) in CDDP/5-FU and 30 pts (71%) in CP. Reported Serious Adverse Events : 62% in CDDP/5-FU and 36% in CP, p=0.016.


InterAACT is the first prospective randomised trial in this setting. In this pick the winner design CP demonstrated similar response rate but less toxicity thus is declared the winner. We have successfully demonstrated the feasibility of international collaboration in a rare cancer. These data establish CP as a standard of care for 1st line treatment of advanced SCCA & serve as a future backbone for the addition of novel agents in phase II/III trials.

Clinical trial identification


Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.